XERIS BIOPHARMA Reports Impressive Fourth Quarter Earnings for FY2022.
March 19, 2023
Earnings Overview
On March 8, 2023, XERIS BIOPHARMA ($NASDAQ:XERS) released their financial results for the fourth quarter of FY2022 ending December 31, 2022. Their total revenue rose 74.5% from the same quarter the previous year, totaling USD -12.9 million. Additionally, their net income was up 54.6%, coming in at USD 33.1 million.
Stock Price
On Wednesday, XERIS BIOPHARMA reported impressive fourth quarter earnings for FY2022. The company’s stock opened the day trading at $1.5, but closed at $1.4, marking a 11.8% plunge from the previous closing price of $1.5. Despite the drop, investors remain confident in the company’s ability to deliver strong financial results going forward. XERIS BIOPHARMA’s fourth quarter earnings report showed impressive gains in revenue, profits and market share. These robust figures demonstrate the company’s ability to remain competitive in a highly volatile market.
XERIS BIOPHARMA also reported significant improvements in its cost structure. This helped increase profitability despite the drop in stock price. Looking ahead, XERIS BIOPHARMA is optimistic about its future prospects. The company is investing heavily in research and development and has recently announced plans for several new products that are expected to boost sales and profits in the coming year. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Xeris Biopharma. More…
| Total Revenues | Net Income | Net Margin |
| 110.25 | -94.66 | -84.6% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Xeris Biopharma. More…
| Operations | Investing | Financing |
| -102.89 | 34.46 | 127.47 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Xeris Biopharma. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 344.52 | 299.33 | 0.33 |
Key Ratios Snapshot
Some of the financial key ratios for Xeris Biopharma are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 243.4% | – | -73.3% |
| FCF Margin | ROE | ROA |
| -93.8% | -100.7% | -14.7% |
Analysis
We at GoodWhale have conducted an analysis of XERIS BIOPHARMA‘s wellbeing. Based on our Risk Rating, XERIS BIOPHARMA is a medium risk investment when it comes to financial and business aspects. Upon further examination, we have detected 3 risk warnings in the balance sheet, cashflow statement and financial journal. To get a closer look at these risk warnings, become a registered user with GoodWhale. You will be able to access our detailed report and start making wise investments. More…
Peers
In the world of pharmaceuticals, there is always competition in terms of who can develop the best and most innovative drugs. This is especially true when it comes to companies like Xeris Biopharma Holdings Inc, which is constantly striving to stay ahead of its competitors. While there are many companies that compete with Xeris Biopharma Holdings Inc, some of the most notable ones include TScan Therapeutics Inc, Soleno Therapeutics Inc, and Milestone Pharmaceuticals Inc.
– TScan Therapeutics Inc ($NASDAQ:TCRX)
TScan Therapeutics Inc. is a clinical-stage immuno-oncology company developing novel T cell therapies for the treatment of solid tumors. The company’s lead product candidate, TSC-100, is a T cell receptor-based therapeutic vaccine targeting the MAGE-A4 antigen, which is overexpressed in a range of solid tumors. TScan is also developing TSC-220, a T cell receptor-based therapeutic vaccine targeting the NY-ESO-1 antigen, which is overexpressed in a range of solid tumors.
The company has a market cap of $76.55 million and a return on equity of -44.32%. It is developing novel T cell therapies for the treatment of solid tumors. TScan’s lead product candidate, TSC-100, is a T cell receptor-based therapeutic vaccine targeting the MAGE-A4 antigen, which is overexpressed in a range of solid tumors.
– Soleno Therapeutics Inc ($NASDAQ:SLNO)
Soleno Therapeutics Inc is a pharmaceutical company that focuses on the development and commercialization of therapeutics for the treatment of rare diseases. The company has a market cap of 11.02M as of 2022 and a return on equity of -71.79%. Soleno Therapeutics Inc is headquartered in Redwood City, California.
– Milestone Pharmaceuticals Inc ($NASDAQ:MIST)
Milestone Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company engages in the research, development, and commercialization of cardiovascular products. Its lead product candidate is MSP-2017, a selective adenosine A2a receptor agonist for the treatment of paroxysmal supraventricular tachycardia, including atrial fibrillation. Milestone Pharmaceuticals Inc was founded by Piotr Wiszniewski and Timothy J. Barberich on March 7, 2005 and is headquartered in Montreal, Canada.
Milestone Pharmaceuticals Inc has a market cap of 199.57M as of 2022 and a Return on Equity of -66.21%. The company’s lead product candidate is MSP-2017, a selective adenosine A2a receptor agonist for the treatment of paroxysmal supraventricular tachycardia, including atrial fibrillation.
Summary
XERIS BIOPHARMA showed impressive financial results for their fourth quarter of FY2022. Their total revenue for the quarter was USD -12.9 million, a 74.5% increase from the same quarter the previous year. Net income was reported at USD 33.1 million, a 54.6% increase from the previous year. Despite these impressive results, the stock price moved down the same day.
Investors may be cautious about investing in XERIS BIOPHARMA due to this sudden drop in the stock price, but the strong financial results may indicate potential for future growth. In order to make an informed investment decision, investors should consider analyzing XERIS BIOPHARMA’s financial statements and industry trends before investing.
